Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LGND
Previous Symbol
CUSIP53220K50
Phone858-550-7500
Debt
Debt-to-Equity Ratio0.86
Current Ratio2.20
Quick Ratio2.19
Price-To-Earnings
Trailing P/E Ratio57.03
Forward P/E Ratio24.80
P/E Growth1.23
Sales & Book Value
Annual Sales$141.10 million
Price / Sales22.07
Cash Flow$3.7952 per share
Price / Cash Flow38.62
Book Value$18.94 per share
Price / Book7.74
Profitability
EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins73.78%
Return on Equity26.17%
Return on Assets10.68%
Miscellaneous
Employees39
Outstanding Shares21,250,000
Market Cap$3.09 billion
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.03 by $0.29. The biotechnology company had revenue of $45.66 million for the quarter, compared to analysts' expectations of $41.99 million. Ligand Pharmaceuticals had a net margin of 73.78% and a return on equity of 26.17%. The firm's revenue for the quarter was up 36.8% compared to the same quarter last year. During the same period last year, the company earned $0.69 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $6.52-6.52 for the period, compared to the Thomson Reuters consensus estimate of $6.37. The company issued revenue guidance of $240-240 million, compared to the consensus revenue estimate of $234.8 million.
What price target have analysts set for LGND?
6 brokers have issued 1-year price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $195.00 to $300.00. On average, they expect Ligand Pharmaceuticals' share price to reach $256.6667 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand reported encouraging third-quarter results, beating estimates on both counts. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, Ligand’s internal pipeline has several candidates in development that could generate future licensing opportunities. Ligand is acquiring other technology platforms to reduce dependence on Captisol formulation. Shares of Ligand have significantly outperformed the industry this year so far. The company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Both the drugs have shown encouraging growth with blockbuster potential. However, any setback related to either of these products could have a substantial impact." (11/15/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $281 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 178 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (11/5/2018)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Media headlines about LGND stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Are investors shorting Ligand Pharmaceuticals?
Ligand Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,582,948 shares, an increase of 36.6% from the October 15th total of 4,087,344 shares. Based on an average daily volume of 757,557 shares, the days-to-cover ratio is currently 7.4 days. Currently, 27.0% of the shares of the stock are short sold. View Ligand Pharmaceuticals' Current Options Chain.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX) and GALAPAGOS NV/S (GLPG).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 48)
- Mr. Matthew W. Foehr, Pres & COO (Age 45)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.86%), Vanguard Group Inc. (9.84%), William Blair Investment Management LLC (4.88%), Janus Henderson Group PLC (4.27%), Renaissance Technologies LLC (3.57%) and Conestoga Capital Advisors LLC (2.68%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Glenmede Trust Co. NA, William Blair Investment Management LLC, Victory Capital Management Inc., Rice Hall James & Associates LLC, First Light Asset Management LLC, Man Group plc and Russell Investments Group Ltd.. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Rehmann Capital Advisory Group, BlackRock Inc., Vanguard Group Inc., Conestoga Capital Advisors LLC, Matarin Capital Management LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $146.57.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $3.09 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
